Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.
2.

Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2013 Aug;54(8):1202-8. doi: 10.2967/jnumed.112.116426. Epub 2013 May 31.

3.

18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.

Haug AR, Tiega Donfack BP, Trumm C, Zech CJ, Michl M, Laubender RP, Uebleis C, Bartenstein P, Heinemann V, Hacker M.

J Nucl Med. 2012 Mar;53(3):371-7. doi: 10.2967/jnumed.111.096230. Epub 2012 Feb 13.

4.

Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.

Piduru SM, Schuster DM, Barron BJ, Dhanasekaran R, Lawson DH, Kim HS.

J Vasc Interv Radiol. 2012 Jul;23(7):943-8. doi: 10.1016/j.jvir.2012.04.010. Epub 2012 May 19.

PMID:
22609292
5.

Total Lesion Glycolysis and Sequential (90)Y-Selective Internal Radiation Therapy in Breast Cancer Liver Metastases: Preliminary Results.

Bagni O, Filippi L, Pelle G, Cianni R, Schillaci O.

Cancer Biother Radiopharm. 2015 Dec;30(10):421-6. doi: 10.1089/cbr.2015.1877. Epub 2015 Nov 23.

PMID:
26594900
6.

Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.

Kucuk ON, Soydal C, Lacin S, Ozkan E, Bilgic S.

World J Surg Oncol. 2011 Aug 6;9:86. doi: 10.1186/1477-7819-9-86. Erratum in: World J Surg Oncol. 2011;9:120.

7.

Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma.

Filippi L, Pelle G, Cianni R, Scopinaro F, Bagni O.

Nucl Med Biol. 2015 Jan;42(1):59-64. doi: 10.1016/j.nucmedbio.2014.08.011. Epub 2014 Aug 19.

PMID:
25213104
8.

Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.

Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ.

Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):815-20. Epub 2002 Mar 29.

PMID:
12029557
9.

Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.

Sabet A, Meyer C, Aouf A, Sabet A, Ghamari S, Pieper CC, Mayer K, Biersack HJ, Ezziddin S.

Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):370-6. doi: 10.1007/s00259-014-2935-z. Epub 2014 Oct 29.

PMID:
25351506
10.

The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review.

Annunziata S, Treglia G, Caldarella C, Galiandro F.

ScientificWorldJournal. 2014 Feb 2;2014:879469. doi: 10.1155/2014/879469. eCollection 2014. Review.

11.

The prognostic value of functional tumor volume and total lesion glycolysis in patients with colorectal cancer liver metastases undergoing 90Y selective internal radiation therapy plus chemotherapy.

Gulec SA, Suthar RR, Barot TC, Pennington K.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1289-95. doi: 10.1007/s00259-011-1758-4. Epub 2011 Apr 2.

PMID:
21461737
12.

Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.

Szyszko T, Al-Nahhas A, Canelo R, Habib N, Jiao L, Wasan H, Pagou M, Tait P.

Nucl Med Commun. 2007 Jan;28(1):15-20.

PMID:
17159544
13.

The role of early ¹⁸F-FDG PET/CT in prediction of progression-free survival after ⁹⁰Y radioembolization: comparison with RECIST and tumour density criteria.

Zerizer I, Al-Nahhas A, Towey D, Tait P, Ariff B, Wasan H, Hatice G, Habib N, Barwick T.

Eur J Nucl Med Mol Imaging. 2012 Sep;39(9):1391-9. doi: 10.1007/s00259-012-2149-1. Epub 2012 May 30.

PMID:
22644713
14.

Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease.

Turkmen C, Ucar A, Poyanli A, Vatankulu B, Ozkan G, Basaran M, Serin K, Sanli Y, Adalet I.

Cancer Biother Radiopharm. 2013 Sep;28(7):534-40. doi: 10.1089/cbr.2012.1455. Epub 2013 May 6.

PMID:
23647219
15.

Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.

Eaton BR, Kim HS, Schreibmann E, Schuster DM, Galt JR, Barron B, Kim S, Liu Y, Landry J, Fox T.

J Vasc Interv Radiol. 2014 Feb;25(2):288-95. doi: 10.1016/j.jvir.2013.08.021. Epub 2013 Oct 23.

PMID:
24269792
16.

Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT.

Kucuk ON, Soydal C, Araz M, Bilgic S, Ibis E.

Clin Nucl Med. 2013 Jul;38(7):e283-9. doi: 10.1097/RLU.0b013e3182867f17.

PMID:
23531737
17.

Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.

Correa-Gallego C, Gavane S, Grewal R, Cercek A, Klimstra DS, Gewirtz AN, Kingham TP, Fong Y, DeMatteo RP, Allen PJ, Jarnagin WR, Kemeny N, D'Angelica MI.

HPB (Oxford). 2015 Jul;17(7):644-50. doi: 10.1111/hpb.12421. Epub 2015 May 23.

18.

Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.

Shady W, Kishore S, Gavane S, Do RK, Osborne JR, Ulaner GA, Gonen M, Ziv E, Boas FE, Sofocleous CT.

Eur J Radiol. 2016 Jun;85(6):1224-31. doi: 10.1016/j.ejrad.2016.03.029. Epub 2016 Mar 31.

PMID:
27161074
19.

Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases.

Muralidharan V, Kwok M, Lee ST, Lau L, Scott AM, Christophi C.

J Nucl Med. 2012 Sep;53(9):1345-51. doi: 10.2967/jnumed.112.102749. Epub 2012 Jul 13.

20.

90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.

Bienert M, McCook B, Carr BI, Geller DA, Sheetz M, Tutor C, Amesur N, Avril N.

Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):778-87. Epub 2005 Mar 17.

PMID:
15772860

Supplemental Content

Support Center